Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL) Healthcare & Pipeline Overview

Charles River Laboratories International, Inc. is a leading non-clinical contract research organization providing drug discovery, non-clinical development, and safety testing services. Operating across three segments, RMS, DSA, and Manufacturing, CRL supports pharmaceutical and biotechnology companies in bringing new therapies to market, serving a global client base.

What Is the Investment Thesis for CRL?

Charles River Laboratories International, Inc. presents a compelling investment case due to its pivotal role in the drug development pipeline. The company's diverse service offerings, spanning research models, discovery, safety assessment, and manufacturing, provide multiple revenue streams and reduce reliance on any single area. The increasing demand for outsourced research and development services in the pharmaceutical and biotechnology industries, driven by cost pressures and the need for specialized expertise, should fuel CRL's growth. However, the company's negative profit margin of -4.6% warrants careful monitoring. Key catalysts include continued expansion in high-growth areas like biologics testing and strategic acquisitions to broaden service offerings. The company's beta of 1.62 indicates higher volatility compared to the market.

Based on FMP financials and quantitative analysis

CRL Key Highlights

• Charles River Laboratories operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions, providing diversified revenue streams.
• The company's services are crucial for pharmaceutical and biotechnology companies, supporting drug discovery, non-clinical development, and safety testing.
• Charles River Laboratories serves a global client base, with operations in the United States, Europe, Canada, and the Asia Pacific region.
• The company's gross margin stands at 31.9%, indicating its ability to maintain profitability despite a negative profit margin of -4.6%.
• Charles River Laboratories has a market capitalization of $11.13B, reflecting its significant presence in the contract research organization (CRO) market.

Who Are CRL's Competitors?

CRL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRL's Key Strengths?

• Comprehensive service offerings across the drug development continuum.
• Global presence and established relationships with key pharmaceutical and biotechnology companies.
• Strong reputation for quality and reliability.
• Expertise in specialized areas like genetically engineered models and biologics testing.

What Are CRL's Weaknesses?

• Negative profit margin of -4.6%.
• High beta of 1.62 indicates higher volatility compared to the market.
• Dependence on the pharmaceutical and biotechnology industries.
• Potential for regulatory scrutiny and compliance issues.

What Could Drive CRL Stock Higher?

• Increasing demand for outsourced research and development services in the pharmaceutical and biotechnology industries.
• Potential for strategic acquisitions to expand service offerings and geographic reach.
• Growth in high-growth areas like biologics testing and cell and gene therapy.
• Expansion in emerging markets, particularly in the Asia Pacific region.

What Are the Key Risks for CRL?

• Negative return on equity (-5.7%) — the business is not currently generating profit on shareholder capital.
• Insider selling — insiders were net sellers of roughly $15.2M recently.
• Intense competition from other contract research organizations.
• Economic downturns that could reduce research and development spending.
• Changes in regulatory requirements or drug approval processes.
• Product liability claims or reputational damage.
• Negative profit margin of -4.6% requires careful monitoring and corrective action.

What Are the Growth Opportunities for CRL?

• Expansion in Biologics Testing: The increasing development of biologic drugs presents a significant growth opportunity for Charles River Laboratories. Biologics require specialized testing and quality control, driving demand for CRL's manufacturing solutions segment. The global biologics market is projected to reach $420 billion by 2026, offering substantial revenue potential for CRL through expanded testing services and strategic partnerships with biotechnology companies.
• Strategic Acquisitions: Charles River Laboratories can pursue strategic acquisitions to expand its service offerings and geographic reach. Acquiring companies with complementary capabilities in areas like cell and gene therapy testing or advanced imaging would strengthen CRL's competitive position and accelerate growth. A well-executed acquisition strategy could add $100-200 million in annual revenue within the next 3-5 years.
• Growth in Asia Pacific: The Asia Pacific region represents a high-growth market for contract research services, driven by increasing healthcare spending and a growing biopharmaceutical industry. Charles River Laboratories can expand its presence in the region through strategic investments in infrastructure and partnerships with local companies. This expansion could increase revenue from the Asia Pacific region by 15-20% annually over the next 5 years.
• Leveraging Genetically Engineered Models and Services (GEMS): The demand for genetically engineered models is increasing as researchers seek more precise and predictive tools for drug discovery. CRL's expertise in GEMS positions it to capitalize on this trend. By expanding its GEMS offerings and developing new models for specific disease areas, CRL can attract new clients and increase revenue from its RMS segment. The GEMS market is expected to grow at a CAGR of 8-10% over the next 5 years.
• Contract Vivarium Operation Services: Charles River Laboratories provides contract vivarium operation services to biopharmaceutical clients, offering a comprehensive solution for managing animal research facilities. This service allows clients to focus on their core research activities while outsourcing the operational aspects of vivarium management. Expanding this service offering can generate recurring revenue and strengthen client relationships. The contract vivarium market is estimated at $1.5 billion and growing.

What Opportunities Does CRL Have?

• Expansion in high-growth areas like biologics testing and cell and gene therapy.
• Strategic acquisitions to broaden service offerings and geographic reach.
• Growth in emerging markets, particularly in the Asia Pacific region.
• Increased outsourcing of research and development activities by pharmaceutical and biotechnology companies.

What Threats Does CRL Face?

• Intense competition from other contract research organizations.
• Economic downturns that could reduce research and development spending.
• Changes in regulatory requirements or drug approval processes.
• Potential for product liability claims or reputational damage.

What Are CRL's Competitive Advantages?

• Established reputation and long-standing relationships with pharmaceutical and biotechnology companies.
• Comprehensive suite of services spanning the entire drug development pipeline.
• Global presence with operations in key markets, including the United States, Europe, and Asia Pacific.
• Specialized expertise in research models, drug discovery, and safety assessment.
• Proprietary technologies and intellectual property in areas like genetically engineered models.

What Does CRL Do?

Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories International, Inc. has evolved into a critical partner for pharmaceutical and biotechnology companies worldwide. The company operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment focuses on producing and selling rodent research models, including strains and purpose-bred rats and mice, essential for preclinical research. The DSA segment provides early and in vivo discovery services, aiding in the identification and validation of novel drug targets and therapeutic candidates. This segment also offers comprehensive safety assessment services, including toxicology, pathology, and bioanalysis. The Manufacturing segment delivers in vitro methods for quality control testing of pharmaceuticals and consumer products, along with specialized testing of biologics and avian vaccine services. Charles River's comprehensive suite of services supports clients from the earliest stages of drug discovery through the manufacturing process, making it a vital player in the healthcare industry.

What Products and Services Does CRL Offer?

• Provides research models and services, including rodent research model strains.
• Offers genetically engineered models and services to support drug discovery.
• Delivers early and in vivo discovery services for identifying drug targets.
• Conducts safety assessment services, including toxicology and pathology.
• Provides bioanalysis, drug metabolism, and pharmacokinetics services.
• Offers in vitro methods for quality control testing of pharmaceuticals.
• Provides specialized testing of biologics for pharmaceutical companies.
• Offers avian vaccine services, including SPF fertile chicken eggs and chickens.

How Does CRL Make Money?

• Generates revenue through the sale of research models and related services.
• Earns fees for providing drug discovery and safety assessment services.
• Receives payments for manufacturing solutions, including quality control testing.
• Contracts with biopharmaceutical companies to operate vivarium facilities.

What Industry Does CRL Operate In?

Charles River Laboratories International, Inc. operates within the rapidly growing contract research organization (CRO) market. The pharmaceutical and biotechnology industries are increasingly outsourcing research and development activities to CROs to reduce costs, improve efficiency, and access specialized expertise. This trend is driven by the rising complexity of drug development and the need for faster time-to-market. The CRO market is highly competitive, with key players like Revvity, Inc. and Qiagen N.V. Charles River differentiates itself through its comprehensive service offerings, spanning from research models to manufacturing solutions, and its global presence.

Who Are CRL's Key Customers?

• Pharmaceutical companies developing new drugs.
• Biotechnology companies researching and developing biologics.
• Academic and research institutions conducting preclinical studies.
• Government agencies involved in drug regulation and research.

Charles River Laboratories International, Inc. Financial Trajectory

Charles River Laboratories International, Inc. (CRL) reported $995.8M in revenue for Q1 2026, reflecting 0.2% growth compared to the prior quarter. The company recorded a net loss of $14.8M, with diluted EPS of $-0.30. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, CRL averaged $-0.94 in diluted EPS.

Company Profile

Charles River Laboratories International, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Wilmington, US. The company is led by CEO James C. Foster. CRL has traded publicly since 2000.

How Charles River Laboratories International, Inc. Is Valued

Charles River Laboratories International, Inc. carries a market capitalization of $11.13B, placing it in the large-cap category. Relative to its peer group, CRL's quantitative score of 59/100 is below the peer average of 72/100.

ROE -6%Key Financial Metrics

Return on equity for Charles River Laboratories International, Inc. stands at -5.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Charles River Laboratories International, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.21 places it in the grey zone, a middle ground that warrants monitoring.

8/8 beatsEarnings Track Record

Charles River Laboratories International, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 10.2% above estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Charles River Laboratories International, Inc. revenue of about $3.85B for fiscal 2026, with EPS near $11.10. The estimate reflects 9 contributing analysts.

Net sellingInsider Activity

Over the past six months, Charles River Laboratories International, Inc. insiders filed 15 SEC Form 4 transactions — 7 sales and 8 purchases. On net that is roughly 66K shares disposed (about $15.2M), a signal worth weighing alongside the fundamentals.

CRL Financials

CRL Latest News

CRL Analyst Consensus

CRL MoonshotScore

Latest Charles River Laboratories International, Inc. Analysis

Charles River Laboratories International, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources